Paper Details

  1. Home
  2. Paper Details

Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer.

Author: BlandezJuan F, Estepa-FernándezAlejandra, GalianaIrene, García-FernándezAlba, Lérida-VisoAraceli, Martínez-MáñezRamón, OrzáezMar, Sancenon-GalarzaFélix

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the potential of combining senescence induction with senolysis to improve outcomes in triple-negative breast cancer (TNBC). The results showed that combining the senescence-inducer palbociclib with the senolytic agent navitoclax effectively delayed tumor growth and reduced metastases in a mouse xenograft model. The authors also explored the use of a galacto-conjugated navitoclax prodrug (nav-Gal) to minimize the side effects associated with navitoclax. This targeted approach resulted in the eradication of senescent TNBC cells with reduced tumor growth, while minimizing navitoclax cytotoxicity.
Paper Details　
Original Abstract of the Article :
Triple-negative breast cancer (TNBC) is a very aggressive subtype of breast cancer with a poor prognosis and limited effective therapeutic options. Induction of senescence, arrest of cell proliferation, has been explored as an effective method to limit tumor progression in metastatic breast cancer. ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.phrs.2022.106628

データ提供：米国国立医学図書館（NLM）

Combination Therapy for Triple-Negative Breast Cancer: A New Approach to Senescence

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with limited treatment options. This study explores the potential of combining senescence induction and senolysis, the removal of senescent cells, as a therapeutic approach for TNBC. The researchers demonstrate that combining palbociclib, a senescence inducer, with navitoclax, a senolytic agent, effectively delays tumor growth and reduces metastasis in a mouse model of TNBC. They also propose a strategy to minimize the side effects associated with navitoclax by using a galacto-conjugated prodrug that can be selectively activated by β-galactosidase, an enzyme overexpressed in senescent cells.

A Novel Approach to Treating Triple-Negative Breast Cancer

This study offers a promising new approach to treating TNBC by combining senescence induction and senolysis. It's like creating a two-pronged attack on a desert sandstorm - first, induce the storm to slow down, then remove the sand particles causing the damage.

Improving Outcomes for Triple-Negative Breast Cancer Patients

This research has the potential to improve outcomes for TNBC patients by providing a more effective and less toxic treatment approach. It's like finding a hidden oasis in the desert of TNBC research, offering a glimmer of hope for better treatment options.

Dr.Camel's Conclusion

This study presents a novel and potentially transformative approach to TNBC treatment, offering a glimmer of hope in the ongoing battle against this aggressive cancer. It's a journey into a new frontier of cancer therapy, and the results are encouraging.
Date :
  1. Date Completed 2023-01-17
  2. Date Revised 2023-02-03
Further Info :

Pubmed ID

36566002

DOI: Digital Object Identifier

10.1016/j.phrs.2022.106628

Related Literature

Article Analysis
・Side Effects of palbociclib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.